FDA Warns Clinical Researcher for Enrolling Ineligible Subjects

Clinical Trials Advisor
A A
The FDA issued a warning letter to a Texas clinical researcher, claiming he deviated from his own investigational plan by enrolling ineligible trial subjects.

To View This Article:

Login

Subscribe To Clinical Trials Advisor